Mirum Pharmaceuticals Stock In The News
| MIRM Stock | USD 44.28 0.28 0.63% |
Our overall analysis of Mirum Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Mirum Pharmaceuticals. The specific impact of Mirum Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Mirum Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Mirum Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Mirum Pharmaceuticals Backtesting and Mirum Pharmaceuticals Hype Analysis. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.
Mirum |
Mirum Pharmaceuticals Today Top News and Investor Outlook
Mirum Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Mirum and other traded companies coverage with news coverage. We help investors stay connected with Mirum headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Mirum Stock performance. Please note that trading solely based on the Mirum Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Mirum Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Mirum earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Mirum Pharmaceuticals that are available to investors today. That information is available publicly through Mirum media outlets and privately through word of mouth or via Mirum internal channels. However, regardless of the origin, that massive amount of Mirum data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Mirum Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Mirum Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Mirum Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Mirum Pharmaceuticals alpha.
Mirum Largest EPS Surprises
Earnings surprises can significantly impact Mirum Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-07 | 2024-06-30 | -0.47 | -0.52 | -0.05 | 10 | ||
2024-05-08 | 2024-03-31 | -0.48 | -0.54 | -0.06 | 12 | ||
2020-11-12 | 2020-09-30 | -0.98 | -0.86 | 0.12 | 12 | ||
2023-05-04 | 2023-03-31 | -0.94 | -0.8 | 0.14 | 14 | ||
2024-11-04 | 2024-09-30 | -0.45 | -0.2979 | 0.1521 | 33 | ||
2022-05-05 | 2022-03-31 | -1.34 | -1.17 | 0.17 | 12 |
Mirum Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Mirum Pharmaceuticals Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
12th of March 2025
Acquisition by Heron Patrick J of 758 shares of Mirum Pharmaceuticals at 42.6642 subject t... at MacroaxisInsider
11th of March 2025
Acquisition by Heron Patrick J of 963 shares of Mirum Pharmaceuticals at 43.7748 subject t... at businesswire.com
7th of March 2025
Acquisition by Heron Patrick J of 580 shares of Mirum Pharmaceuticals at 43.2145 subject t... at thelincolnianonline.com
6th of March 2025
Acquisition by Heron Patrick J of 1335 shares of Mirum Pharmaceuticals at 43.8928 subject ... at gurufocus.com
5th of March 2025
Acquisition by Heron Patrick J of 267 shares of Mirum Pharmaceuticals at 44.545 subject to... at thelincolnianonline.com
28th of February 2025
Decoding Mirum Pharmaceuticals Inc A Strategic SWOT Insight at gurufocus.com
27th of February 2025
MIRMs Q4 Loss Wider Than Expected, Revenues Beat Estimates at finance.yahoo.com
26th of February 2025
Mirum Pharmaceuticals reports Q4 results at seekingalpha.com
24th of February 2025
CSTL Gears Up to Report Q4 Earnings Heres What You Should Know at zacks.com
3rd of February 2025
Disposition of 1064 shares by Jolanda Howe of Mirum Pharmaceuticals at 48.2225 subject to ... at MacroaxisInsider
13th of January 2025
Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Bala... at businesswire.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mirum Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mirum Pharmaceuticals' short interest history, or implied volatility extrapolated from Mirum Pharmaceuticals options trading.
Check out Mirum Pharmaceuticals Backtesting and Mirum Pharmaceuticals Hype Analysis. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) | Revenue Per Share | Quarterly Revenue Growth 0.429 | Return On Assets | Return On Equity |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.